Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112529 - CAR-T CELLS HAVING HUMANIZED CD19 SCFV WITH MUTATION IN CDR 1 REGION

Publication Number WO/2020/112529
Publication Date 04.06.2020
International Application No. PCT/US2019/062755
International Filing Date 22.11.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/0011
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 2319/03
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
01containing a localisation/targetting motif
03containing a transmembrane segment
Applicants
  • PROMAB BIOTECHNOLOGIES, INC. [US]/[US]
  • FOREVERTEK BIOTECHNOLOGY CO., LTD [CN]/[CN]
Inventors
  • WU, Lijun
  • GOLUBOVSKAYA, Vita
Agents
  • KUNG, Viola, T.
  • ARAIZA, Alberto
  • BECKER, Jordan, M.
  • CHEN, Han-Wei, (Harvey)
  • COLEMAN, Brian, R.
  • FOWLER, Colin, M.
  • FULLER, Thomas
  • GLENN, Michael, A.
  • HANKS, Mackenzie
  • PETROVIC, Lena
  • PETTIT, Andrew, T.
  • SCHUNTER, Kristen
  • THOMAS, Julia, A.
Priority Data
62/773,11229.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CAR-T CELLS HAVING HUMANIZED CD19 SCFV WITH MUTATION IN CDR 1 REGION
(FR) CELLULES CAR-T AYANT UN SCFV CD19 HUMANISÉ AVEC MUTATION DANS LA RÉGION CDR 1
Abstract
(EN)
The present invention is directed to a monoclonal anti-human CD19 antibody, or a single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 7. The present invention is also directed to a CD19 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The monoclonal antibody of the present invention exhibits selective and high-affinity binding to CD19. CD19-CAR T cells based on humanized scFv of the present invention are useful to treat patients with B-cell malignancies including leukemia and lymphomas.
(FR)
La présente invention concerne un anticorps monoclonal anti-CD19 humain, ou un fragment variable monocaténaire (scFv), comprenant VH ayant la séquence d’acides aminés de SEQ ID NO : 6 et VL ayant la séquence d’acides aminés SEQ ID NO : 7 La présente invention concerne en outre un récepteur d’antigène chimérique (CAR) CD19 comprenant, de l’extrémité N-terminale à l’extrémité C-terminale : (i) un fragment variable monocaténaire (scFv) de la présente invention, (ii) un domaine transmembranaire, (iii) au moins un domaine costimulateur, et (iv) un domaine d’activation. L’anticorps monoclonal de la présente invention présente une liaison sélective et à haute affinité à CD19. Les cellules CAR-T CD19 à base de scFv humanisé de la présente invention sont utiles pour traiter des patients atteints de malignités à cellules B, comprenant une leucémie et des lymphomes.
Latest bibliographic data on file with the International Bureau